Home » Topics » BioWorld Science, Endocrine/metabolic

BioWorld Science, Endocrine/metabolic
RSS

Kyowa Hakko presents new antidiabetic agents

Feb. 11, 2004

Novel androgen receptor agonists under study at Kaken

Feb. 11, 2004

BioXell and ProSkelia join efforts in osteoporosis drug discovery

Feb. 11, 2004

New PPAR agonists and their use reported by GSK researchers

Feb. 10, 2004

Pfizer presents new ERbeta-selective SERM in a recent patent

Feb. 10, 2004

Novel NPY Y1 inhibitor from Bristol-Myers Squibb

Feb. 10, 2004

Lilly presents new selective and dual PPAR modulators

Feb. 9, 2004

Selective and dual PPARalpha/PPARgamma agonists developed at AstraZeneca

Feb. 9, 2004

Further evidence for the antiovulatory effects of CDB-2914 in healthy women

Feb. 9, 2004

ABX-PTH enters phase I trial in patients with secondary hyperparathyroidism

Feb. 6, 2004

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 29, 2026.
ENCALS 2026: From genetics to advancing strategies against ALS
BioWorld Science
Amyotrophic lateral sclerosis (ALS)-associated genes provide direct therapeutic targets and reveal pathways that can be used to develop treatments that counteract...
Next wave of BCI firms builds on pioneers to tackle challenges
BioWorld
With the pace of neurotechnology development accelerating, a wave of brain-computer interface (BCI) companies is emerging on the heels of the pioneers. In the...
Elixirgen and Nippon Shinyaku sign EXG-7001 option agreement
BioWorld Science
Elixirgen Therapeutics Inc. has entered into an option agreement with Nippon Shinyaku Co. Ltd. for the development and commercialization of EXG-7001 for Duchenne...
Investors bet on transformative BCI tech for neuro disorders
BioWorld
An estimated $2 billion has been invested in the brain-computer interface (BCI) space in the last two years and the level of funding is expected to continue....